None listed
Conditions
Interventions
Drug : In the DUR-based group, patients with a history of macrolide (clarithromycin, azithromycin, erythromycin, roxithromycin, dirithromycin, josamycin, midecamycin, rokitamycin, spiramycin) use, as
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with confirmed H. pylori infection who meet the indication for eradication therapy and agree to provide their personal prescription and dispensing information to healthcare providers. Patients with confirmed H. pylori infection who meet the indication for eradication therapy and agree to undergo endoscopy and PCR testing. Patients who have received an explanation of the study's purpose, methods, and effects and voluntarily signed a written informed consent form.
Exclusion criteria
Exclusion criteria: i) Patients younger than 19 years or older than 79 years. ii) Patients with a history of gastrectomy. iii) Patients with a prior history of H. pylori eradication therapy. iv) Patients with known adverse reactions to the antibiotics used in this study. v) Pregnant or breastfeeding women. vi) Patients deemed unsuitable for the clinical trial based on the investigator’s judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of eradication rates between tailored therapy based on macrolide exposure and tailored therapy based on PCR test results (Intention-To-Treat, Per-Protocol analysis | — |
Secondary
| Measure | Time frame |
|---|---|
| compliance;adverse event | — |
Countries
Korea, Republic of
Contacts
Public ContactHaeri Jo
Asan Medical Center
Outcome results
None listed